These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36736784)

  • 1. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
    Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
    Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
    Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
    Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
    Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
    Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
    Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
    Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
    La Rosa C; Chiuppesi F; Park Y; Zhou Q; Yang D; Gendzekhadze K; Ly M; Li J; Kaltcheva T; Ortega Francisco S; Gutierrez MA; Ali H; Otoukesh S; Amanam I; Salhotra A; Pullarkat VA; Aldoss I; Rosenzweig M; Aribi AM; Stein AS; Marcucci G; Dadwal SS; Nakamura R; Forman SJ; Al Malki MM; Diamond DJ
    Front Immunol; 2023; 14():1114131. PubMed ID: 36936918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
    Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
    Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    Clin Infect Dis; 2024 Aug; 79(2):542-554. PubMed ID: 38801746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
    Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
    Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
    Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
    Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
    Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Humoral Response in Kidney Transplant Recipients and Donors and Healthy Volunteers Following Second Dose of SARS-CoV-2 mRNA Vaccine.
    Sasaki H; Hasegawa K; Harada H; Takamoto D; Takada Y; Hirano T; Tanabe T; Tanaka H; Miura M
    Transplant Proc; 2023 Apr; 55(3):514-520. PubMed ID: 36948961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
    Aleissa MM; Little JS; Davey S; Saucier A; Zhou G; Gonzalez-Bocco IH; Crombie JL; Looka A; Baden LR; Issa NC; Hammond SP; Jacobson CA; Sherman AC
    Transplant Cell Ther; 2023 Jun; 29(6):398.e1-398.e5. PubMed ID: 36906276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
    Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
    Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].
    Nagafuji K
    Rinsho Ketsueki; 2022; 63(9):1067-1077. PubMed ID: 36198531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.